Recently, it has been shown that the addition of midostaurin, the first US FDA approved FLT3 inhibitor, to standard chemotherapy significantly improved overall survival in young adult patients with AML and FLT3 mutations 21. This evidence concerns the gene FLT3 and acute myeloid leukemia.